Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 0.53 |
| ▸ | PARP2 | Q9UGN5 | 10/20 | 0.52 |
| ▸ | PARP6 | Q2NL67 | 6/20 | 0.52 |
| ▸ | PARP3 | Q9Y6F1 | 6/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1160664 | 0.92 | PARP1 (0.56) | PARP1PARP2PARP6PARP3 | |
| SCHEMBL1160533 | 0.91 | PARP1 (0.54) | PARP1PARP2PARP6PARP3TIPARP | |
| SCHEMBL1160802 | 0.91 | PARP1 (0.53) | PARP1PARP2PARP6PARP3 | |
| SCHEMBL1160656 | 0.91 | PARP1 (0.53) | PARP1PARP2PARP6PARP3 | |
| SCHEMBL1160510 | 0.91 | PARP1 (0.53) | PARP1PARP2PARP6PARP3TIPARP | |
| SCHEMBL1160599 | 0.89 | PARP1 (0.52) | PARP1PARP2PARP6PARP3 | |
| SCHEMBL1160650 | 0.89 | PARP1 (0.52) | PARP1PARP2PARP6PARP3 | |
| SCHEMBL1160776 | 0.89 | PARP1 (0.52) | PARP1PARP2PARP6PARP3 | |
| SCHEMBL1160731 | 0.89 | PARP1 (0.56) | PARP1PARP2PARP6PARP3KCNH2 | |
| SCHEMBL1160803 | 0.88 | PARP1 (0.58) | PARP1PARP2PARP6PARP3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541417-B2 | Poly (ADP-ribose) polymerase (PARP) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-09-24 | — | — | US | claimed |
| EP-2459561-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2012-06-06 | — | — | EP | claimed |
| US-20120129868-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-24 | — | — | US | claimed |
| WO-2011014681-A1 | Poly (ADP-Ribose) Polymerase (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-03 | — | — | WO | claimed |
| US-8980902-B2 | Poly (ADP-ribose) polymerase (PARP) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-03-17 | — | — | US | disclosed |
| US-8980902-B2 | Poly (ADP-ribose) polymerase (PARP) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-03-17 | — | — | US | disclosed |
| US-20140024654-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-23 | — | — | US | disclosed |
| US-20140024654-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-23 | — | — | US | disclosed |
| US-8541417-B2 | Poly (ADP-ribose) polymerase (PARP) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-09-24 | — | — | US | disclosed |
| US-8541417-B2 | Poly (ADP-ribose) polymerase (PARP) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-09-24 | — | — | US | disclosed |
| US-20120129868-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-24 | — | — | US | disclosed |
| US-20120129868-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129868-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | PARP1, PARP2, PARP3 | PARP1 1/4885PARP2 2/4885PARP6 4/4885 |
| US-20140024654-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | PARP1, PARP2, PARP3 | PARP1 1/4885PARP2 2/4885PARP6 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.